Daratumumab (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Daratumumab" in Portuguese language version.

refsWebsite

Global rank Portuguese rank

16doi.org

2^nd place

4^th place

15nih.gov

4^th place

8^th place

3web.archive.org

1^st place

2europa.eu

68^th place

56^th place

1gov.br

5,564^th place

168^th place

1who.int

195^th place

150^th place

1jnj.com

low place

1genmab.com

low place

1medscape.com

719^th place

598^th place

1centerwatch.com

low place

1businesswire.com

615^th place

1,182^nd place

1fda.gov

447^th place

869^th place

1healio.com

low place

1harvard.edu

18^th place

51^st place

1worldcat.org

5^th place

1springer.com

274^th place

339^th place

1medpagetoday.com

9,274^th place

low place

1myelomabeacon.com

low place

businesswire.com

«Janssen's Single-Agent Darzalex (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)». 23 de maio de 2016. Consultado em 23 de maio de 2016 – via Business Wire

centerwatch.com

«Darzalex New FDA Drug Approval». CenterWatch. Consultado em 4 de junho de 2019. Arquivado do original em 5 de agosto de 2019

doi.org

dx.doi.org

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. (setembro de 2015). «Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma». The New England Journal of Medicine. 373 (13): 1207–1219. PMID 26308596. doi:10.1056/NEJMoa1506348
Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, et al. (março de 2022). «Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT». Bone Marrow Transplantation. 57 (3): 499–501. PMID 35013536. doi:10.1038/s41409-021-01560-y
Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. (2019). «Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma». PLOS ONE. 14 (2): e0211927. Bibcode:2019PLoSO..1411927N. PMC 6374018. PMID 30759167. doi:10.1371/journal.pone.0211927
Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, et al. (agosto de 2019). «Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma». Annals of Hematology. 98 (8): 1999–2001. PMID 30824957. doi:10.1007/s00277-019-03645-7
Jain A, Ramasamy K (setembro de 2020). «Evolving Role of Daratumumab: From Backbencher to Frontline Agent». Clinical Lymphoma, Myeloma & Leukemia. 20 (9): 572–587. PMID 32331971. doi:10.1016/j.clml.2020.03.010
Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. (junho de 2015). «Resolving the daratumumab interference with blood compatibility testing». Transfusion. 55 (6 Pt 2): 1545–1554. PMID 25764134. doi:10.1111/trf.13069
Perincheri S, Torres R, Tormey CA, Smith BR, Rinder HM, Siddon AJ (2 de dezembro de 2016). «Daratumumab Interferes with Flow Cytometric Evaluation of Multiple Myeloma». Blood. 128 (22). 5630 páginas. ISSN 0006-4971. doi:10.1182/blood.V128.22.5630.5630
Dhillon S (junho de 2020). «Isatuximab: First Approval». Drugs. 80 (9): 905–912. PMID 32347476. doi:10.1007/s40265-020-01311-1
Konen JM, Fradette JJ, Gibbons DL (dezembro de 2019). «The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors». Cells. 9 (1). 52 páginas. PMC 7016859. PMID 31878283. doi:10.3390/cells9010052
Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, et al. (junho de 2020). «CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond». International Journal of Molecular Sciences. 21 (11). 4129 páginas. PMC 7312896. PMID 32531894. doi:10.3390/ijms21114129
Mistry JJ, Moore JA, Kumar P, Marlein CR, Hellmich C, Pillinger G, et al. (fevereiro de 2021). «Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells». Haematologica. 106 (2): 589–592. PMC 7849566. PMID 32193250. doi:10.3324/haematol.2019.242974
Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, et al. (novembro de 2019). «Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab». Cells. 8 (12). 1522 páginas. PMC 6953105. PMID 31779273. doi:10.3390/cells8121522
Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, et al. (julho de 2019). «Daratumumab in multiple myeloma». Cancer. 125 (14): 2364–2382. PMID 30951198. doi:10.1002/cncr.32065
Franssen LE, Stege CA, Zweegman S, van de Donk NW, Nijhof IS (abril de 2020). «Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma». Journal of Clinical Medicine. 9 (4). 1195 páginas. PMC 7230744. PMID 32331242. doi:10.3390/jcm9041195
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. (outubro de 2016). «Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma». The New England Journal of Medicine. 375 (14): 1319–1331. PMID 27705267. doi:10.1056/NEJMoa1607751
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. (agosto de 2016). «Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma». The New England Journal of Medicine. 375 (8): 754–766. PMID 27557302. doi:10.1056/NEJMoa1606038

europa.eu

ema.europa.eu

«An overview of Darzalex and why it is authorised in the EU» (PDF). www.ema.europa.eu. 2018. Consultado em 4 de junho de 2019
«SUMMARY OF PRODUCT CHARACTERISTICS» (PDF). www.ema.europa.eu. Consultado em 4 de junho de 2019

fda.gov

«Daratumumab (Darzalex)». U.S. Food and Drug Administration (FDA). 9 de fevereiro de 2019

genmab.com

ir.genmab.com

«Daratumumab Receives Breakthrough Therapy Designation from US Food and Drug Administration». Genmab A/S. 1 de maio de 2013. Consultado em 10 de janeiro de 2017. Arquivado do original em 13 de janeiro de 2017

gov.br

«Dalinvi (daratumumabe): nova indicação». Agência Nacional de Vigilância Sanitária - Anvisa. Consultado em 8 de julho de 2022

harvard.edu

ui.adsabs.harvard.edu

Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. (2019). «Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma». PLOS ONE. 14 (2): e0211927. Bibcode:2019PLoSO..1411927N. PMC 6374018. PMID 30759167. doi:10.1371/journal.pone.0211927

healio.com

«FDA approves Darzalex for newly diagnosed, transplant-ineligible multiple myeloma». www.healio.com. Consultado em 8 de maio de 2018

jnj.com

«Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab». Janssen Biotech. Consultado em 31 de janeiro de 2013

medpagetoday.com

«ASCO: Drug Shows Promise in Myeloma». MedPage Today

medscape.com

«Daratumumab Approved for Multiple Myeloma in US». Medscape

myelomabeacon.com

«Daratumumab Continues To Show Promise For Relapsed/Refractory Myeloma Patients (ASH 2012)». The Myeloma Beacon. Consultado em 31 de janeiro de 2013

nih.gov

ncbi.nlm.nih.gov

Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. (setembro de 2015). «Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma». The New England Journal of Medicine. 373 (13): 1207–1219. PMID 26308596. doi:10.1056/NEJMoa1506348
Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, et al. (março de 2022). «Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT». Bone Marrow Transplantation. 57 (3): 499–501. PMID 35013536. doi:10.1038/s41409-021-01560-y
Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. (2019). «Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma». PLOS ONE. 14 (2): e0211927. Bibcode:2019PLoSO..1411927N. PMC 6374018. PMID 30759167. doi:10.1371/journal.pone.0211927
Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, et al. (agosto de 2019). «Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma». Annals of Hematology. 98 (8): 1999–2001. PMID 30824957. doi:10.1007/s00277-019-03645-7
Jain A, Ramasamy K (setembro de 2020). «Evolving Role of Daratumumab: From Backbencher to Frontline Agent». Clinical Lymphoma, Myeloma & Leukemia. 20 (9): 572–587. PMID 32331971. doi:10.1016/j.clml.2020.03.010
Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. (junho de 2015). «Resolving the daratumumab interference with blood compatibility testing». Transfusion. 55 (6 Pt 2): 1545–1554. PMID 25764134. doi:10.1111/trf.13069
Dhillon S (junho de 2020). «Isatuximab: First Approval». Drugs. 80 (9): 905–912. PMID 32347476. doi:10.1007/s40265-020-01311-1
Konen JM, Fradette JJ, Gibbons DL (dezembro de 2019). «The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors». Cells. 9 (1). 52 páginas. PMC 7016859. PMID 31878283. doi:10.3390/cells9010052
Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, et al. (junho de 2020). «CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond». International Journal of Molecular Sciences. 21 (11). 4129 páginas. PMC 7312896. PMID 32531894. doi:10.3390/ijms21114129
Mistry JJ, Moore JA, Kumar P, Marlein CR, Hellmich C, Pillinger G, et al. (fevereiro de 2021). «Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells». Haematologica. 106 (2): 589–592. PMC 7849566. PMID 32193250. doi:10.3324/haematol.2019.242974
Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, et al. (novembro de 2019). «Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab». Cells. 8 (12). 1522 páginas. PMC 6953105. PMID 31779273. doi:10.3390/cells8121522
Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, et al. (julho de 2019). «Daratumumab in multiple myeloma». Cancer. 125 (14): 2364–2382. PMID 30951198. doi:10.1002/cncr.32065
Franssen LE, Stege CA, Zweegman S, van de Donk NW, Nijhof IS (abril de 2020). «Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma». Journal of Clinical Medicine. 9 (4). 1195 páginas. PMC 7230744. PMID 32331242. doi:10.3390/jcm9041195
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. (outubro de 2016). «Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma». The New England Journal of Medicine. 375 (14): 1319–1331. PMID 27705267. doi:10.1056/NEJMoa1607751
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. (agosto de 2016). «Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma». The New England Journal of Medicine. 375 (8): 754–766. PMID 27557302. doi:10.1056/NEJMoa1606038

springer.com

adisinsight.springer.com

«Daratumumab - Janssen Biotech - AdisInsight». adisinsight.springer.com

web.archive.org

World Health Organization (2009). «International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101» (PDF). WHO Drug Information. 23 (2). Cópia arquivada (PDF) em 17 de dezembro de 2010
«Daratumumab Receives Breakthrough Therapy Designation from US Food and Drug Administration». Genmab A/S. 1 de maio de 2013. Consultado em 10 de janeiro de 2017. Arquivado do original em 13 de janeiro de 2017
«Darzalex New FDA Drug Approval». CenterWatch. Consultado em 4 de junho de 2019. Arquivado do original em 5 de agosto de 2019

who.int

whqlibdoc.who.int

World Health Organization (2009). «International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101» (PDF). WHO Drug Information. 23 (2). Cópia arquivada (PDF) em 17 de dezembro de 2010

worldcat.org

Perincheri S, Torres R, Tormey CA, Smith BR, Rinder HM, Siddon AJ (2 de dezembro de 2016). «Daratumumab Interferes with Flow Cytometric Evaluation of Multiple Myeloma». Blood. 128 (22). 5630 páginas. ISSN 0006-4971. doi:10.1182/blood.V128.22.5630.5630